Hugo Fry

Managing Director, Sanofi UK

Hugo is Managing Director of Sanofi UK and General Manager of Sanofi Pasteur in the UK. Prior to assuming this role, Hugo was the Chief Marketing Officer for Sanofi Pasteur MSD (SPMSD), leading the commercial effort for the European vaccine Joint Venture since 2015. Hugo Fry has been a member of the ABPI Board of Management since December 2016 and is currently the Board sponsor for both vaccines and the Prescription Medicines Code of Practice Authority (PMCPA). He is also a member of the ABPI Governance Committee. Hugo began his career in the pharmaceutical industry in the UK in 1993 in sales and marketing until moving to Paris to pursue General Management, Global Commercial, R&D and Strategic roles. Hugo joined Aventis UK in 2003 as Head of Commercial Excellence. Beginning in 2007, Hugo spent four years in Russia leading Sanofi’s Diabetes, Oncology, Cardiovascular, Internal Medicine and Consumer Healthcare businesses, where he was also responsible for the acquisition and set up of an insulin manufacturing facility in addition to other strategic BD and licencing deals. Following a strategic acquisition, he was then appointed General Manager of Zentiva Russia, where he was instrumental in maintaining Zentiva as one of the fastest growing companies in Russia while integrating into the Sanofi Group. Hugo then joined the Sanofi Diabetes Leadership Team as Global project Leader for the lixisenatide family, heading R&D, Industrial affairs and commercial operations before assuming his role at SPMSD. Hugo holds a B.Sc. in Chemistry from the University of Salford and Studied Finance at London Business School.